| Drug ID: | Drug80 |
|---|---|
| Drug Name: | Curcumin |
| CID: | 969516 |
| DrugBank ID: | DB11672 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NO |
| Other Approved: | NO |
| Identifier: | NCT00889161, , NCT04713631 |
| Molecular Formula: | C21H20O6 |
| Molecular Weight: | 368.4 g/mol |
| Isomeric SMILES: | COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O |
| Synonyms: | curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Gelbwurz; Haldar; Curcumin I; Souchet |
| Phase 0: | 11 |
| Phase 1: | 38 |
| Phase 2: | 67 |
| Phase 3: | 23 |
| Phase 4: | 14 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt675 | 969516 | Curcumin | 4843 | NOS2 | Homo sapiens (human) | None | |
| dt676 | 969516 | Curcumin | 765 | CA6 | Homo sapiens (human) | None | |
| dt677 | 969516 | Curcumin | 1576 | CYP3A4 | Homo sapiens (human) | None | |
| dt678 | 969516 | Curcumin | 4318 | MMP9 | Homo sapiens (human) | None | |
| dt679 | 969516 | Curcumin | 1789 | DNMT3B | Homo sapiens (human) | None | |
| dt680 | 969516 | Curcumin | 1786 | DNMT1 | Homo sapiens (human) | None | |
| dt681 | 969516 | Curcumin | 351 | APP | Homo sapiens (human) | None | |
| dt682 | 969516 | Curcumin | 759 | CA1 | Homo sapiens (human) | None | |
| dt683 | 969516 | Curcumin | 5743 | PTGS2 | Homo sapiens (human) | None | |
| dt684 | 969516 | Curcumin | 5594 | MAPK1 | Rattus norvegicus (Norway rat) | 11981161 | Curcumin inhibits the reaction [tetracaine results in increased phosphorylation of MAPK1 protein] |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02683759 | Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative Colitis | PHASE3 | UNKNOWN | Asian Institute of Gastroenterology, India | Ulcerative Colitis | DIETARY_SUPPLEMENT: Bio-enhanced Curcumin Soft Ge… | Details |
| NCT02683733 | Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis | PHASE3 | UNKNOWN | Asian Institute of Gastroenterology, India | Ulcerative Colitis | DIETARY_SUPPLEMENT: Bio-enhanced Curcumin Soft Ge… | Details |
| NCT01320436 | Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis | PHASE3 | COMPLETED | Sheba Medical Center | Ulcerative Colitis | DIETARY_SUPPLEMENT: Curcumin|DRUG: 5-aminosalicyl… | Details |
| NCT03122613 | Curcumin for Prevention of Relapse in Patients With Ulcerative Colitis | None | TERMINATED | Chinese University of Hong Kong | Ulcerative Colitis in Remission | DIETARY_SUPPLEMENT: Curcumin|DRUG: Placebo | Details |
| NCT04713631 | Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease | PHASE2 | RECRUITING | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Crohn's Disease | DRUG: Artesunate|DRUG: Curcumin|DRUG: Placebo A|D… | Details |
| NCT06867939 | A Pilot Study of Curcumin (Soloways in Patients With Inflammatory Bowel Disease Homozygous for the IL-10 Variant | Not Available | Not recruiting | S.LAB (SOLOWAYS) | Inflamatory Bowel Disease | Dietary Supplement: liposomal curcumin;Dietary Su… | Details |
| RBR-89q4ydz | Effect of supplementation with Curcuma Longa (extract) and Piperine on inflammatory markers, oxidative stress and glycoxidation in patients with Inflammatory Bowel Disease treated at a Teaching Hospital in Alagoa | Not Available | Not Recruiting | Universidade Federal de Alagoas | Inflammatory Bowel Disease | This is a double-blind randomized clinical trial.… | Details |
| NCT04879810 | Pilot Clinical Trial Investigating the Ability of Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease (IBD) | Not Available | Not recruiting | University of Louisville | Irritable Bowel Disease | Procedure: Sigmoidoscopy and biopsy, blood work | Details |
| JPRN-UMIN000015770 | Randomized double-blind multicenter study for anti-inflammatory effects of highly bioavailable curcumin on Crohn's disease. - Exploratory study for effects of highly bioavailable curcumin on Crohn's disease. | Not Available | Not Recruiting | Hamamatsu South Hospital, Centre for Gastroenterology and Inflammatory Bowel Disease Research | Crohn's disease (180 <= CDAI < 450) … | Standard therapy for Crohn's disease (Pentasa… | Details |
| NCT00889161 | Curcumin in Pediatric Inflammatory Bowel Disease | PHASE1 | COMPLETED | Seattle Children's Hospital | Inflammatory Bowel Disease|Ulcerative Colitis|Cro… | DRUG: Curcumin | Details |
| NCT05761327 | Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis | None | COMPLETED | Ardahan University | Ulcerative Colitis | OTHER: Mediterranean Diet|DIETARY_SUPPLEMENT: Cur… | Details |
| NCT02277223 | Curcumin in Pediatric Ulcerative Colitis | PHASE3 | WITHDRAWN | Schneider Children's Medical Center, Israel | Ulcerative Colitis | DIETARY_SUPPLEMENT: Curcumin|DRUG: Placebo | Details |
| NCT03500653 | Curcumin Supplementation as an Add on Treatment for Patients With Inflammatory Bowel Diseases Treated With Vedolizumab | None | UNKNOWN | Henit Yanai | Inflammatory Bowel Diseases | DIETARY_SUPPLEMENT: Curcumin|DIETARY_SUPPLEMENT: … | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S05 | Angiogenesis | cell proliferation; vascular permeability | ozanimod | The bioactive lipid S1P has been shown to activate NF-κB an… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Antioxidant and anti-inflammatory activity of curcumin transdermal gel in an IL…
PMID: 36477991
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel diseases are a group of inflammatory disorders of the gastrointestinal tract. Their prevalence is still low in Brazil, but the inc…
Curcumin alleviates experimental colitis via a potential mechanism involving me…
PMID: 36353208
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Immune dysfunction is the crucial cause in the pathogenesis of inflammatory bowel disease (IBD), which is mainly related to lymphocytes (…
Correlation of Macrophages with Inflammatory Reaction in Ulcerative Colitis and…
PMID: 36302234
Year: 2023
Relationship Type:
Treatment
Score: 6.5
OBJECTIVE: Our study aimed to elucidate the correlation of macrophage (mo) with the inflammatory reaction in ulcerative colitis (UC) and the influenc…
Curcumin analog C66 alleviates inflammatory colitis by inhibiting the activatio…
PMID: 36261684
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: The pathogenesis of inflammatory bowel disease (IBD) remains unclear. C66, a derivative of curcumin, reportedly exerts anti-inflammatory,…
Effect of curcumin on regulatory B cells in chronic colitis mice involving TLR/…
PMID: 36196887
Year: 2023
Relationship Type:
Mechanism
Score: 6.5
Curcumin (Cur) is a natural active phenolic compound extracted from the root of Curcuma Longa L. It has anti-inflammatory, anti-tumor and other pharm…
Sequential self-assembly and disassembly of curcumin hydrogel effectively allev…
PMID: 36190132
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disorder of the gastrointestinal tract with unclear etiology and insufficien…
Anti-inflammatory effects of β-ionone-curcumin hybrid derivatives against ulcer…
PMID: 36156276
Year: 2022
Relationship Type:
Association
Score: 6.5
A series of beta-ionone-curcumin hybrid derivatives were designed and chosen to merge the biological characteristics of two parent molecules and to o…
Oral delivery of curcumin via multi-bioresponsive polyvinyl alcohol and guar gu…
PMID: 36099999
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Anti-inflammatory drugs for ulcerative colitis (UC) treatment should specifically penetrate and accumulate in the colon tissue. Herein, a multi-biore…
Curcumin and Curcuma longa Extract in the Treatment of 10 Types of Autoimmune D…
PMID: 35979355
Year: 2022
Relationship Type:
Treatment
Score: 6.5
OBJECTIVE: To evaluate the randomized controlled trials (RCTs) of Curcumin and Curcuma longa Extract in the treatment of autoimmune diseases. METHODS…
Protective Effects of Curcumin-Regulated Intestinal Epithelial Autophagy on Inf…
PMID: 35529035
Year: 2022
Relationship Type:
Treatment
Score: 6.5
OBJECTIVE: This study was aimed at exploring the ameliorating effect of curcumin (Cur) on inflammatory bowel disease (IBD) in mice induced by 3% dext…
Starch nanoparticles improve curcumin-induced production of anti-inflammatory c…
PMID: 35295898
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a long-term condition resulting from self-sustained intesti…
Efficacy and safety of adjuvant curcumin therapy in ulcerative colitis: A syste…
PMID: 35091013
Year: 2022
Relationship Type:
Treatment
Score: 6.5
ETHNOPHARMACOLOGICAL RELEVANCE: Curcumin, an active polyphenol extracted from Traditional Chinese medicine Curcuma longa (turmeric), has shown many h…
Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran…
PMID: 34931590
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Comment in Int J Dermatol. 2023 Mar;62(3):e159-e161. AIMS: Adalimumab is a biological therapy used to treat different chronic inflammatory dise…
Effects of curcumin supplementation on inflammatory biomarkers in patients with…
PMID: 34478838
Year: 2021
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Although previous studies have examined the impact of curcumin supplementation on cytokine levels in patients with autoimmune disorders, …
Identification of the Molecular Basis of Nanocurcumin-Induced Telocyte Preserva…
PMID: 34373677
Year: 2021
Relationship Type:
Association
Score: 6.5
BACKGROUND: Telocytes (TCs) are a distinct type of interstitial cells that play a vital role in the pathogenesis of ulcerative colitis and colonic ti…
A Systematic Review of the Clinical Use of Curcumin for the Management of Gastr…
PMID: 34331698
Year: 2021
Relationship Type:
Adverse Effect
Score: 6.5
Gastrointestinal (GI) diseases are highly prevalent worldwide, with considerable morbidity and mortality. Curcumin has been used for many years as a …
A review of therapeutic potentials of turmeric (Curcuma longa) and its active c…
PMID: 34312922
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Turmeric (Curcuma longa) and its constituent, curcumin, have been used for their therapeutic properties for a long time. Most of the medicinal impact…
Commensal flora triggered target anti-inflammation of alginate-curcumin micelle…
PMID: 33865087
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Ulcerative colitis (UC) is a chronic, idiopathic inflammatory bowel disease characterized by dysregulation of colon immune response. Curcumin (Cur) h…
Chitosan-based nanocarriers for encapsulation and delivery of curcumin: A review
PMID: 33667554
Year: 2021
Relationship Type:
Treatment
Score: 6.5
To overcome the poor aqueous solubility and bioavailability of curcumin, emphasize its functional features, and broaden its applications in the food …
Oral nanotherapeutics with enhanced mucus penetration and ROS-responsive drug r…
PMID: 33471012
Year: 2021
Relationship Type:
Treatment
Score: 6.5
The therapeutic efficacies of oral nanotherapeutics for ulcerative colitis (UC) are seriously hindered by the lack of mucus-penetrating capacity and …